Shire Says Investors More Favorable Now To Baxalta Bid
This article was originally published in Scrip
Executive Summary
Shire PLC's large investors are more on board with the firm's pursuit of Baxalta Inc. than they were when the bid first was announced in August, and the specialty pharma says it will continue to seek a merger that would create a rare disease powerhouse with 30 new products and $20bn in annual revenue by 2020.